Baylor University Medical Center
Hematology and Oncology fellowship · Dallas, TX · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is Baylor University Medical Center's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
About Baylor University Medical Centerinstitution-wide hematology and oncology research
Hematology and Oncology publications from Baylor University Medical Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
35
works per year
59th of 74 hematology and oncology fellowship programs
+12.1%
2-year growth
36th of 74 hematology and oncology fellowship programs
31.4%
in top 10% of field (works before 2025)
11th of 72 hematology and oncology fellowship programs
48.0%
cited above world average
17th of 72 hematology and oncology fellowship programs
Works per year · * 2026 so far
Oncology · 116Hematology · 54
Hematology and Oncology research topics at Baylor University Medical Center
Papers in the window; each links to the list on OpenAlex.
- Cancer Immunotherapy and Biomarkers 22
- Advanced Breast Cancer Therapies 15
- Pancreatic and Hepatic Oncology Research 13
- Erythropoietin and Anemia Treatment 13
- Hematopoietic Stem Cell Transplantation 11
- Iron Metabolism and Disorders 11
- Colorectal Cancer Surgical Treatments 10
- Cutaneous Melanoma Detection and Management 10
Most cited at Baylor University Medical Center since 2024
All hematology and oncology papers there on OpenAlex
- Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy OutcomesPriya Rastogi et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 236
- Imlunestrant with or without Abemaciclib in Advanced Breast CancerKomal L. Jhaveri et al. · New England Journal of Medicine · 2024 · PubMed · cited 229
- Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analysesRonan Joseph Kelly et al. · Nature Medicine · 2024 · PubMed · cited 133
- Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1 -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical SubgroupsAditya Bardia et al. · Clinical Cancer Research · 2024 · PubMed · cited 124
- First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 StudySusanna Hegewisch‐Becker et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 67
- Redefining Iron Deficiency in Patients With Chronic Heart FailureMilton Packer et al. · Circulation · 2024 · PubMed · cited 63
- PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trialMark N. Stein et al. · Nature Communications · 2024 · PubMed · cited 53
- Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE studyMatthew Philip Goetz et al. · npj Breast Cancer · 2024 · PubMed · cited 46
- Immune-related encephalitis after immune checkpoint inhibitor therapyMonica Weaver Buckley et al. · The Oncologist · 2024 · PubMed · cited 38
- Identification of three mechanistic pathways for iron-deficient heart failureMilton Packer et al. · European Heart Journal · 2024 · PubMed · cited 37